home icon

right icon

Stocks

right icon

ASTRAZEN

ASTRAZEN

ASTRAZEN

Pharmaceuticals & Drugs

3342.75

0.00 (0.00%)

stock change
Market Cap8,342 CrEPS36.9High3350
Stock P/E90.5Net Profit MarginNALow3303.75
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
explain

Astrazeneca Pharma Price chart

explain

NSE: Astrazeneca Pharma

explain

Performance

Today’s Low

Today’s High

3303.75

3350

52W Low

52W High

2445.7

3620

Open Price3320.95Volume3
Prev. Close3320.95
explain

Fundamentals

explain
Market Cap8,342 CrROE22.8%
P/E Ratio(TTM)90.5EPS(TTM)NA
P/B Ratio15.3Dividend Yield0.3%
Industry P/E65.2Book Value217.5
Face Value2.0
explain

About the Company

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Parent OrganisationAstrazeneca Pharma India Ltd.Managing DirectorGagandeep Singh Bedi
Founded1979NSE SymbolASTRAZEN
explain

Shareholding Pattern

explain

Peer Comparison

Company52 WeekMarket PriceP/E Ratio
SEE MORE
explain

Recently Viewed

No Recently Viewed Stocks
explain

Frequently asked questions

You can buy the shares of Astrazeneca Pharma using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.